Systematic review finds limited but promising evidence for cannabis in fibromyalgia

Across four RCTs and five observational studies totaling 564 patients, cannabis showed low-quality evidence of short-term pain reduction in fibromyalgia, with only one RCT finding no difference from placebo.

Strand, Natalie H et al.·Biomedicines·2023·Moderate EvidenceSystematic Review
RTHC-04963Systematic ReviewModerate Evidence2023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Moderate Evidence
Sample
N=564

What This Study Found

Of four RCTs examining cannabis for fibromyalgia, three showed benefit over placebo for pain. Observational studies supported these findings. However, evidence quality was low and studies were small.

Key Numbers

564 total patients across 9 studies (4 RCTs, 5 observational). Three of four RCTs showed cannabis outperformed placebo for pain outcomes. Literature searched through October 2022.

How They Did This

Systematic review following PRISMA guidelines. Searched MEDLINE, EMBASE, Cochrane, and Scopus using MeSH terms. Included four RCTs and five observational studies totaling 564 patients.

Why This Research Matters

Fibromyalgia affects millions and current treatments often fall short. This systematic review provides the most structured look at whether cannabis could fill that gap, even if the evidence base remains thin.

The Bigger Picture

Many fibromyalgia patients already use cannabis, often without clinical guidance. Building a proper evidence base requires larger, longer RCTs with standardized cannabis formulations and consistent outcome measures.

What This Study Doesn't Tell Us

Low overall evidence quality. Small sample sizes across studies. Heterogeneous cannabis preparations and dosing. Short study durations. Observational studies prone to expectation bias.

Questions This Raises

  • ?Which cannabinoid profiles work best for fibromyalgia?
  • ?Do benefits persist beyond the short-term windows studied?
  • ?How does cannabis compare to approved fibromyalgia medications head-to-head?

Trust & Context

Key Stat:
3 of 4 RCTs showed cannabis outperformed placebo for fibromyalgia pain
Evidence Grade:
Systematic review with multiple RCTs, though small sample sizes and low evidence quality limit the strength of conclusions.
Study Age:
Published 2023. Literature search through October 2022.
Original Title:
Cannabis for the Treatment of Fibromyalgia: A Systematic Review.
Published In:
Biomedicines, 11(6) (2023)
Database ID:
RTHC-04963

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does cannabis help fibromyalgia?

The evidence is promising but weak. Three of four randomized controlled trials found cannabis reduced pain more than placebo, but studies were small and short-term. The systematic review rates the overall evidence as low quality.

Is cannabis safe for fibromyalgia patients?

The review describes cannabis as appearing safe in the short term for fibromyalgia patients, but long-term safety data is lacking. Side effects in the included studies were generally mild.

Read More on RethinkTHC

Cite This Study

RTHC-04963·https://rethinkthc.com/research/RTHC-04963

APA

Strand, Natalie H; Maloney, Jillian; Kraus, Molly; Wie, Christopher; Turkiewicz, Michal; Gomez, Diego A; Adeleye, Olufunmilola; Harbell, Monica W. (2023). Cannabis for the Treatment of Fibromyalgia: A Systematic Review.. Biomedicines, 11(6). https://doi.org/10.3390/biomedicines11061621

MLA

Strand, Natalie H, et al. "Cannabis for the Treatment of Fibromyalgia: A Systematic Review.." Biomedicines, 2023. https://doi.org/10.3390/biomedicines11061621

RethinkTHC

RethinkTHC Research Database. "Cannabis for the Treatment of Fibromyalgia: A Systematic Rev..." RTHC-04963. Retrieved from https://rethinkthc.com/research/strand-2023-cannabis-for-the-treatment

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.